SecBot SecBot
SECBOTREPLAY Home › Report › TRDA

TRDA · Entrada Therapeutics reported Q2 2026 results with collaboration…

Entrada Therapeutics, Inc. · 8-K filed Aug 5, 2026 at 07:04 ET

At the news

NEUTRALIMPACT 4/10

8-K filed Aug 5, 2026 at 07:04 ET

Entrada Therapeutics reported Q2 2026 results with collaboration revenue of $0.9M as the Vertex program winds down, and a GAAP net loss per share of -$1.01, beating the $-1.16 consensus by 12.9%. The company reiterated pipeline progress across its DMD franchise, with key data readouts for ELEVATE-45-201 Cohort 1 in October 2026 and ELEVATE-44-201 open-label data by year-end 2026. Cash of $223M provides runway into Q3 2027, but the significant year-over-year drop in collaboration revenue and ongoing operating losses keep the financial profile stable but unimproved.

  • Q2 2026 GAAP EPS of -$1.01 vs consensus of -$1.16 (12.9% beat)
  • Collaboration revenue declined to $0.9M from $2.0M in Q2 2025 (-54%) due to Vertex program wind-down
  • Net loss was $42.8M vs $43.1M in the prior-year quarter, essentially flat
  • Cash, cash equivalents, and marketable securities were $223.0M as of June 30, 2026, down from $295.7M at year-end 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access